Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya.

Mehta SA, Ahmed A, Kariuki BW, Said S, Omasete F, Mendillo M, Laverty M, Holzman R, Valentine F, Sivapalasingam S.

Am J Trop Med Hyg. 2010 Sep;83(3):565-70. doi: 10.4269/ajtmh.2010.09-0629.

2.

Incident neuropathy in HIV-infected patients on HAART.

Nakamoto BK, McMurtray A, Davis J, Valcour V, Watters MR, Shiramizu B, Chow DC, Kallianpur K, Shikuma CM.

AIDS Res Hum Retroviruses. 2010 Jul;26(7):759-65. doi: 10.1089/aid.2009.0276.

3.

Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.

Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, Gelman BB, Vaida F, Collier A, Marra CM, Ances B, Atkinson JH, Dworkin RH, Morgello S, Grant I; CHARTER Study Group.

Arch Neurol. 2010 May;67(5):552-8. doi: 10.1001/archneurol.2010.76.

4.

Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.

van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, Reid T.

Trans R Soc Trop Med Hyg. 2010 Feb;104(2):148-53. doi: 10.1016/j.trstmh.2009.07.009. Epub 2009 Sep 3.

PMID:
19732926
5.

Gender differences in discontinuation of antiretroviral treatment regimens.

Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):336-41. doi: 10.1097/QAI.0b013e3181b628be.

6.

Age and height predict neuropathy risk in patients with HIV prescribed stavudine.

Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S, Kamarulzaman A, Price P.

Neurology. 2009 Jul 28;73(4):315-20. doi: 10.1212/WNL.0b013e3181af7a22.

PMID:
19636052
7.

Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.

Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB.

Neurology. 2009 Jan 13;72(2):165-70. doi: 10.1212/01.wnl.0000339042.96109.86.

8.

[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].

Millogo A, Lankoandé D, Yaméogo I, Yaméogo AA, Sawadogo AB.

Bull Soc Pathol Exot. 2008 Feb;101(1):11-3. French.

PMID:
18431998
9.

Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.

Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL, Chaisson RE, Churchyard GJ, Grant AD.

AIDS. 2008 Jan 2;22(1):67-74.

10.

Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.

Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, Myer L, Egger M, Coetzee D, Maartens G, Wood R; International Epidemiological Databases to Evaluate Aids in Southern Africa Collaboration.

Antivir Ther. 2007;12(5):753-60.

PMID:
17713158
11.

Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya.

Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):304-10.

PMID:
17414931
12.

Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.

Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):456-62.

PMID:
17279048
13.

Improved self-confidence was a mechanism of action in two geriatric trials evaluating physical interventions.

Peduzzi P, Guo Z, Marottoli RA, Gill TM, Araujo K, Allore HG.

J Clin Epidemiol. 2007 Jan;60(1):94-102. Epub 2006 Sep 28.

PMID:
17161760
14.

HIV neuropathy natural history cohort study: assessment measures and risk factors.

Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, So Y, Marra CM, Diaz-Arrastia R, Shriver S, Millar L, Clifford DB; ACTG A5117 Study Group.

Neurology. 2006 Jun 13;66(11):1679-87.

PMID:
16769940
15.

A brief measure of perceived understanding of informed consent in a clinical trial was validated.

Guarino P, Lamping DL, Elbourne D, Carpenter J, Peduzzi P.

J Clin Epidemiol. 2006 Jun;59(6):608-14. Epub 2006 Mar 24.

PMID:
16713523
16.

Human immunodeficiency virus-associated peripheral neuropathies.

Ferrari S, Vento S, Monaco S, Cavallaro T, Cainelli F, Rizzuto N, Temesgen Z.

Mayo Clin Proc. 2006 Feb;81(2):213-9. Review.

PMID:
16471077
17.

Evaluation of a clinical screening tool for HIV-associated sensory neuropathies.

Cherry CL, Wesselingh SL, Lal L, McArthur JC.

Neurology. 2005 Dec 13;65(11):1778-81.

PMID:
16344522
18.

Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana.

Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, Gaolathe T, Mujugira A, Busang L, Vanderwarker C, Cardiello P, Johnson O, Thior I, Mazonde P, Moffat H, Essex M, Marlink R.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):336-43.

PMID:
16249709
19.

Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.

van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE.

Trop Med Int Health. 2005 May;10(5):464-70.

20.

Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.

Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD; HIV Outpatient Study Investigators.

Clin Infect Dis. 2005 Jan 1;40(1):148-57. Epub 2004 Dec 6.

PMID:
15614705

Supplemental Content

Support Center